Pilot Study of Faecal Microbiota Transplantation for Mild to Moderate Alzheimers Disease Assessing Safety and Feasibility Using Colonoscopy Administration

What this Trial Is About

Researchers are evaluating the feasibility and safety of faecal microbiota transplantation FMT for people with Alzheimers disease AD, which is the most common cause of dementia. This study explores the possible link between gut flora and the development or progression of AD, based on evidence that gut flora differs between people with AD and healthy individuals. The study is sponsored by the University Hospital of North Norway and is a phase 1 trial. Participants will receive a preprocessed stool solution from a healthy donor via colonoscopy, where the solution is administered to the right side of the colon. This single-group, open-label study involves one intervention arm using FMT. The procedure is given once during a colonoscopy examination. During the study, participants will be monitored from baseline through 3 months after the FMT procedure. Researchers will assess safety by tracking treatment-related adverse events and feasibility by measuring recruitment rates, colonoscopy completion, and study completion. Cognitive function will be evaluated using various tests like the Clinical Dementia Rating Scale and Montreal Cognitive Assessment. Quality of life and daily living activities will also be assessed to understand the impact of the treatment.

Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study